However, in two pediatric studies on this subject so far, conflicting results emerged. The NOPHO group confirmed that high BAALC expression was an independent prognostic factor for event-free survival (EFS), which, however, did not lead to an overall survival (OS) benefit. ERG expression had no prognostic impact and, in fact, only high-risk cytogenetics predicted for OS in multivariate analysis. 6 In the study by Pigazzi et al., independent prognostic significance of high ERG expression was found in 71 mixed-lineage leukemia (MLL)-rearranged patients, but not when analyzing all patients together, as was later confirmed by the NOPHO group. [6] [7] [8] To study whether we could confirm data obtained in previously published pediatric studies, BAALC and ERG expression levels were analyzed in a cohort of 294 pediatric de novo AML patients, all extensively studied for cytogenetic and molecular abnormalities. 1 We also addressed this question to the CN-AML subgroup specifically. Gene expression levels were determined using the Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA, USA). 1 For BAALC expression levels, two probe sets were available on the Affymetrix arrays, and for ERG, four probe sets were available. Expression levels of BAALC and ERG determined by gene expression profiling (GEP) were validated by quantitative reverse transcriptase PCR (RT-qPCR), using the following primers and probe for BAALC: 5 0 -AAGGCACCAACAGATTCA-3 0 (forward primer), 5 0 -AAGGCCATTCTGTTTCTG-3 0 (reverse primer) and 5 0 -TACAGCCC CAGGTGGAATACC-3 0 (probe). For ERG the following primers were used: 5 0 -GATCCTTATCAGATTCTTGGACCAACA-3 0 (forward) and 5 0 -GGA ACTGCCAAAGCTGGATCT-3 0 (reverse). For further analysis, it was decided to use the probe set with the best correlation between the Affymetrix probe and RT-qPCR for each gene. Probe set 218899_s_at for the BAALC gene and probe set 213541_s_at for the ERG gene were therefore selected. Spearman rank correlation testing for BAALC (n ¼ 110, R s ¼ 0.81, Po0.001) and ERG (n ¼ 110, R s ¼ 0.80, Po0.001) expression levels showed excellent correlations between RT-qPCR and gene expression data for these probes.
To compare our data with results obtained in other studies, the cutoff for BAALC expression was defined by the median expression level, 5 and ERG expression levels were dichotomized into groups including the lower three quartiles (Q1-3) and the upper quartile (Q4) of ERG expression values. 9, 10 The entire cohort was analyzed using cutoff levels obtained on all samples. However, when describing specific cytogenetic or molecular subgroups the cutoff levels were adapted for the particular subgroup of interest. The relation of expression levels of BAALC and ERG with outcome were assessed using the following parameters: EFS (defined as the time between diagnosis and first event, including failure to achieve remission, relapse, death of any cause or secondary malignancy); OS (defined as the time between diagnosis and death) and cumulative incidence of relapse (CIR) (defined as the time between diagnosis and relapse, resistant disease was included as an event on day 0). EFS and OS were determined by the Kaplan-Meier method, and compared using the log-rank test. CIR was calculated using the Kalbfleisch and Prentice method, and compared by the Gray's test. The independency of prognostic Letters to the Editor factors was determined by multivariate Cox regression analysis. P-values p0.05 were considered statistically significant and all tests were two-tailed.
We first analyzed differential BAALC expression in the various AML cytogenetic subgroups. Higher median BAALC expression levels were found in inv(16)(p13;q22) (twofold higher BAALC expression compared with all other AML samples, Po0.001), t(8;21)(q22;q22) (fold difference 2.9, Po0.001) and t(7;12)(q36;p13) (fold difference 2.0, P ¼ 0.002) patients (Figure 1a) . The corebinding factor (CBF) AML subgroup (including inv(16)(p13;q22) and t(8;21)(q22;q22) patients) had significant higher BAALC expression levels (fold difference 2.7) compared with all other samples (Figure 1a ). For ERG, only the t(15;17)(q21;q22) cases had significantly higher expression levels when compared with all other samples (fold difference 2.4, Po0.001), which has not been identified in other studies (Figure 1b) . 6 When comparing BAALC and ERG gene expression levels found in CN-AML patients to all other AML patients, we did not find significantly different expression of either genes. In addition, patients carrying an MLL rearrangement did not have significantly different expression levels compared with the rest of the AML population.
The þ 8 and þ 21 patients were investigated separately, as overexpression of BAALC and ERG were described in adult AML in cases with þ 8 and þ 21 respectively, possibly as a result of a gene-dosage effect. 11, 12 Although patient numbers were small, no higher expression levels of BAALC and ERG were detected in þ 8 and þ 21 cases compared with other AML cases, indicating that there is no clear evidence for a gene-dosage effect, and suggesting a role for posttranslational modification (Figure 1 ).
For survival analysis, patients with PML-RARA and/or FAB M3 (n ¼ 23), patients treated according to other/individualized protocols (n ¼ 28) or lost for follow-up (n ¼ 7) were excluded. This resulted in 236 patients available for survival analysis, including 47 CN-AML and 63 CBF-AML patients.
Univariate survival analysis showed that BAALC expression did not have a significant effect either on 5-year OS, 5-year EFS nor on 5-year CIR. Similarly, ERG expression did not significantly affect survival parameters. Within CN-AML patients, high levels of BAALC expression conferred a significantly lower 5-year OS (BAALC high vs BAALC low , 47±11% vs 76±10%; P ¼ 0.03) and a trend for a lower EFS (BAALC high vs BAALC low , 29±10% vs 50 ± 11%; P ¼ 0.07), as well as a trend for a higher 5-year CIR (62 ± 11% for BAALC high and 37 ± 11% for BAALC low ) (P ¼ 0.07), (Figures 2a-c) when compared with patients with low BAALC expression levels. This is similar to the results found in most adult CN-AML studies whereas ERG expression did not affect survival estimates in CN-AML in our series (Figures 2d-f) . In the CBF-AML subgroup, no significant differences were observed for high vs low expression of BAALC for 5-year OS, 5-year EFS or the 5-year CIR. This was in agreement with other studies that showed significantly higher BAALC expression levels in CBF-AML. 6, 7, 12 However, none of these groups reported prognostic analysis of expression levels in CBF-AML.
In multivariate analysis however, including NPM1 mutation status and NUP98/NSD1 translocations, BAALC was no longer an independent prognostic factor, not for OS (P ¼ 0.26), nor for EFS (P ¼ 0.89), different from most adult and pediatric CN-AML studies. 5 In fact, the only independent predictor for EFS was NUP98/NSD1 (hazard ratio (HR) 4.2; P ¼ 0.004), with a trend for OS (HR 2.7; P ¼ 0.09). The NUP98/ NSD1 fusion gene is known to be a strong denominator of poor outcome in CN-AML; however, including only BAALC expression levels and NPM1 mutations in the analysis did not result in independent prognostic significance for high BAALC expression in CN-AML. We could therefore not confirm the results obtained by Staffas et al. 6 who showed that high BAALC expression was an independent prognostic factor for EFS in the NOPHO study. In addition, we could not demonstrate a prognostic effect of ERG expression levels in MLL-rearranged AML as previously demonstrated in other pediatric studies. 7, 8 These conflicting results may be explained by the fact that patients were enrolled in the different studies and treatment protocols.
The function of BAALC in AML has not been established yet. However, a recent study by Heesch et al., which included adult CN-AML patients, showed that IGFBP7 (insulin-like growth factor-binding protein 7) was co-expressed with BAALC.
13 Therefore we also analyzed IGFBP7 expression levels in relation to the BAALC expression levels. However, in our CN-AML patients and also our total AML cohort, no correlation between IGFBP7 and BAALC was found (P ¼ 0.41 and P ¼ À 0.17, respectively). In addition, IGFBP7 levels were not significantly higher in normal bone marrow (NBM) samples than in AML patient samples (pediatric AML vs NBM, P ¼ 0.10).
In conclusion, high BAALC and ERG expression levels were detected in specific cytogenetic and molecular subgroups of pediatric AML. However, high expression levels did not have independent prognostic significance in our pediatric AML cohort or in the CN-AML subgroup specifically. Therefore we do not consider BAALC and ERG expression levels to be a valuable addition to the existing prognostic markers in pediatric AML.
